Therefore, the goal of the present study was to analyze CD and gluten sensitivity-associated antibodies in a large, well-characterized group of patients with drug-resistant focal epilepsy by categorizing epilepsy patients into three different groups: (i) those with either prior diagnosis of CD or CD-specific TG2/EmA antibodies (CD-positive group), (ii) those with AGA but without CD (AGA-positive group), and (iii) those without any gluten sensitivity-associated antibodies or CD (CD/AGA-negative group). This evidence concerns the gene TGM2 and epilepsy.